Earnings Call Summary | Plexus(PLXS.US) Q2 2024 Earnings Conference
Earnings Call Summary | Plexus(PLXS.US) Q2 2024 Earnings Conference
The following is a summary of the Plexus Corp. (PLXS) Q2 2024 Earnings Call Transcript:
以下是Plexus Corp.(PLXS)2024年第二季度業績電話會議記錄的摘要:
Financial Performance:
財務業績:
Plexus Corp. reported Q2 revenue of $967 million and non-GAAP EPS of $0.94.
The company generated $65 million of free cash flow in Q2, aided by improvements in gross inventory and reduced capital spending.
Their gross margin stood at 9.1% in Q2 due to improvements in fixed cost leverage and productivity.
Plexus Corp expects to achieve a 5.5% GAAP operating margin by fiscal 2025.
It expects to generate similar quantities of free cash flow in Q3 and Q4 while returning to a normalized free cash flow by 2025.
Plexus Corp. 報告第二季度收入爲9.67億美元,非公認會計准則每股收益爲0.94美元。
該公司在第二季度創造了6500萬澳元的自由現金流,這得益於總庫存的改善和資本支出的減少。
由於固定成本槓桿率和生產率的提高,他們在第二季度的毛利率爲9.1%。
Plexus Corp預計,到2025財年,GAAP營業利潤率將達到5.5%。
它預計將在第三季度和第四季度產生類似數量的自由現金流,同時到2025年恢復正常的自由現金流。
Business Progress:
業務進展:
In Q2, Plexus Corp. achieved $255 million in new program wins and expects robust demand in Q3 from the aerospace and defense market sector.
The company is embedding sustainable business practices by participating in the United Nations Global Compact and is a finalist for Glasgow's Net Zero Hero Award.
The company anticipates a strong finish for the current fiscal year and increased momentum leading into FY '25.
Plexus is leveraging advanced AI and ML practices in manufacturing to hasten product innovation.
A trend towards outsourcing amongst their clients, along with their profitability driven by program ramps in the healthcare sector and not market recovery, offers promising prospects for the future.
在第二季度,Plexus Corp. 贏得了2.55億美元的新項目,並預計第三季度航空航天和國防市場領域的需求將強勁。
該公司正在通過參與聯合國全球契約來嵌入可持續的商業慣例,併入圍格拉斯哥淨零英雄獎。
該公司預計,本財年將取得強勁的業績,並將在25財年之前增強勢頭。
Plexus 正在利用製造業中的先進人工智能和機器學習實踐來加速產品創新。
客戶之間外包的趨勢,以及由醫療保健行業項目增加而不是市場復甦推動的盈利能力,爲未來提供了光明的前景。
More details: Plexus IR
更多詳情: Plexus 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。